Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
Cessation
Eculizumab
Myasthenia gravis
Worsening
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
30
06
2020
revised:
29
07
2020
accepted:
05
10
2020
pubmed:
18
10
2020
medline:
17
12
2020
entrez:
17
10
2020
Statut:
ppublish
Résumé
Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. The neuromuscular junction damage associated with MG is caused by anti-acetylcholine receptor (AChR) antibody and complements. Recently, eculizumab (an anti-C5 monoclonal antibody) was approved for patients with anti-AChR antibody-positive generalized refractory MG. Here, we report a Japanese man with MG who well responded to eculizumab, but experienced acute severe worsening of myasthenic symptoms 2 months after its discontinuation. Plasmapheresis did not improve his symptoms; hence, eculizumab was re-administered, resulting in a dramatic response within a week. This is an informative case because eculizumab discontinuation in patients with MG has been very rarely reported. If eculizumab treatment is clinically well effective and AChR antibody titer does not decrease, clinicians should be aware that acute and critical deterioration of MG may occur after the eculizumab discontinuation.
Identifiants
pubmed: 33068973
pii: S0165-5728(20)30685-8
doi: 10.1016/j.jneuroim.2020.577424
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Autoantibodies
0
Complement Inactivating Agents
0
eculizumab
A3ULP0F556
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577424Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.